Article
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
British journal of cancer - 4 Aug 2009
Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt J A, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs C S, Kulke M H, Shivdasani R A
Abstract excerpt
BACKGROUND: We address the prognostic and predictive value of KRAS, PIK3CA and BRAF mutations for clinical outcomes in response to active agents in the treatment of metastatic colorectal cancer (mCRC). METHODS: We determined KRAS, BRAF and PIK3CA mutations in tumours from 168 patients treated for mCRC at two institutions. All patients received 5-FU-based first-line chemotherapy and treatment outcome was analysed...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Cetuximab
- Class I Phosphatidylinositol 3-Kinases
- Colorectal Neoplasms
- Female